Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Kian Behbakht

Concepts (455)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
47
2025
573
5.540
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
10
2025
116
1.610
 Why?
Endometrial Neoplasms
11
2025
202
1.180
 Why?
Drug Resistance, Neoplasm
17
2024
801
1.080
 Why?
Peritoneal Neoplasms
7
2024
97
1.070
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2020
1742
0.890
 Why?
Genital Neoplasms, Female
6
2020
93
0.880
 Why?
Uterine Cervical Neoplasms
8
2017
290
0.850
 Why?
Cystadenocarcinoma, Serous
6
2024
78
0.800
 Why?
Biomarkers, Tumor
9
2025
1229
0.740
 Why?
Hysterectomy
4
2018
141
0.720
 Why?
Neoplasm Recurrence, Local
8
2025
1058
0.720
 Why?
Antineoplastic Agents
10
2023
2152
0.710
 Why?
Fallopian Tube Neoplasms
6
2024
18
0.700
 Why?
TNF-Related Apoptosis-Inducing Ligand
5
2017
49
0.640
 Why?
Gelatin
2
2016
55
0.580
 Why?
Neoplasms, Glandular and Epithelial
3
2015
49
0.570
 Why?
Thrombin
2
2016
158
0.560
 Why?
Models, Economic
1
2018
60
0.560
 Why?
Claudin-4
4
2025
13
0.550
 Why?
Hyperthermia, Induced
1
2018
120
0.530
 Why?
Histone-Lysine N-Methyltransferase
3
2024
134
0.520
 Why?
Cell Line, Tumor
21
2025
3397
0.520
 Why?
Female
88
2025
74016
0.520
 Why?
Pelvic Infection
1
2016
6
0.500
 Why?
Homeodomain Proteins
3
2012
509
0.500
 Why?
Tissue Adhesives
1
2016
22
0.490
 Why?
Cost-Benefit Analysis
1
2018
609
0.470
 Why?
Neoplastic Cells, Circulating
2
2017
77
0.460
 Why?
Women
1
2015
50
0.440
 Why?
Sirolimus
2
2016
277
0.420
 Why?
Vagina
6
2016
193
0.400
 Why?
Middle Aged
50
2025
33782
0.380
 Why?
Humans
92
2025
138972
0.380
 Why?
Antibodies, Neoplasm
1
2012
33
0.370
 Why?
Health Knowledge, Attitudes, Practice
2
2015
1377
0.370
 Why?
Neoplasm Staging
15
2024
1370
0.360
 Why?
Cisplatin
2
2015
327
0.350
 Why?
Aged
38
2025
24172
0.350
 Why?
Aged, 80 and over
19
2025
7685
0.340
 Why?
Pelvic Exenteration
1
2009
11
0.310
 Why?
Neoadjuvant Therapy
4
2020
408
0.310
 Why?
Apoptosis
8
2019
2551
0.310
 Why?
Leiomyosarcoma
3
2020
28
0.310
 Why?
Uterine Neoplasms
4
2019
113
0.300
 Why?
Robotic Surgical Procedures
3
2016
143
0.300
 Why?
Phthalazines
2
2019
45
0.300
 Why?
Paclitaxel
3
2019
237
0.300
 Why?
Cytoreduction Surgical Procedures
2
2020
62
0.300
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
3
2017
30
0.300
 Why?
Pyrimidines
3
2019
472
0.300
 Why?
Tumor Microenvironment
2
2024
668
0.290
 Why?
Carcinoma, Endometrioid
3
2019
50
0.290
 Why?
Health Personnel
1
2015
734
0.280
 Why?
Chemotherapy, Adjuvant
2
2020
374
0.280
 Why?
Carbazoles
1
2008
56
0.280
 Why?
Caffeine
1
2008
66
0.280
 Why?
Gene Expression Regulation, Neoplastic
8
2025
1395
0.280
 Why?
Azepines
2
2019
97
0.280
 Why?
Papanicolaou Test
2
2004
44
0.270
 Why?
Adult
32
2025
38393
0.270
 Why?
Vaginal Smears
2
2004
62
0.260
 Why?
Clinical Competence
1
2015
1149
0.260
 Why?
Protein Kinase C
1
2008
252
0.260
 Why?
Piperazines
2
2019
345
0.260
 Why?
Postoperative Complications
6
2020
2716
0.250
 Why?
Hemostasis, Surgical
2
2016
26
0.230
 Why?
Laparotomy
2
2015
112
0.220
 Why?
Adenocarcinoma
4
2015
882
0.220
 Why?
Urban Health
1
2004
96
0.220
 Why?
Genomic Instability
1
2025
52
0.220
 Why?
Disease-Free Survival
7
2017
704
0.220
 Why?
Indoles
2
2025
411
0.220
 Why?
Fallopian Tubes
1
2024
32
0.210
 Why?
Histocompatibility Antigens
2
2024
106
0.200
 Why?
Pyrazoles
2
2020
425
0.200
 Why?
Prognosis
9
2024
3995
0.200
 Why?
Genetic Therapy
2
2014
314
0.200
 Why?
Lipids
2
2025
675
0.190
 Why?
Uterine Cervical Dysplasia
2
2003
44
0.190
 Why?
Adenocarcinoma, Clear Cell
2
2021
14
0.190
 Why?
Neoplasm Grading
5
2024
305
0.180
 Why?
Leiomyoma
2
2019
77
0.180
 Why?
Radiosurgery
1
2025
389
0.180
 Why?
Hospitals, Public
1
2001
27
0.170
 Why?
Healthcare Disparities
2
2018
662
0.170
 Why?
Piperidines
2
2019
216
0.170
 Why?
BRCA2 Protein
3
2019
62
0.170
 Why?
Early Detection of Cancer
1
2025
429
0.170
 Why?
Hospitals, University
1
2001
175
0.170
 Why?
Vulvar Neoplasms
1
2020
14
0.170
 Why?
Cervix Uteri
3
2011
52
0.170
 Why?
Treatment Outcome
11
2020
10921
0.160
 Why?
Epoxy Compounds
1
2020
31
0.160
 Why?
Machine Learning
1
2025
516
0.160
 Why?
Mutation
5
2019
3984
0.160
 Why?
Carnitine O-Palmitoyltransferase
1
2020
45
0.160
 Why?
Rad51 Recombinase
1
2019
15
0.160
 Why?
Cell Movement
2
2016
969
0.160
 Why?
Enoxaparin
1
2020
64
0.160
 Why?
Up-Regulation
2
2020
852
0.150
 Why?
Vaccines, Conjugate
1
2019
64
0.150
 Why?
Receptors, Adiponectin
1
2019
19
0.150
 Why?
Poly(ADP-ribose) Polymerases
1
2019
98
0.150
 Why?
Neoplasms
4
2017
2687
0.150
 Why?
Interleukin-12
2
2014
123
0.150
 Why?
Pyridones
1
2020
170
0.150
 Why?
Sequence Analysis, RNA
2
2019
449
0.140
 Why?
CD8-Positive T-Lymphocytes
1
2024
910
0.140
 Why?
Lymph Node Excision
2
2020
168
0.140
 Why?
Cancer Vaccines
1
2019
166
0.140
 Why?
Adjuvants, Immunologic
1
2019
237
0.140
 Why?
Cost Savings
1
2018
84
0.140
 Why?
Ovariectomy
2
2015
157
0.140
 Why?
Patient Acceptance of Health Care
1
2004
856
0.140
 Why?
Cell Growth Processes
2
2008
53
0.140
 Why?
Sarcoma
1
2020
189
0.140
 Why?
Oncologists
1
2018
43
0.140
 Why?
Aurora Kinase A
1
2017
55
0.140
 Why?
Dose-Response Relationship, Drug
4
2008
2047
0.140
 Why?
Animals
14
2024
37243
0.140
 Why?
Antineoplastic Agents, Phytogenic
1
2019
191
0.130
 Why?
Breast Neoplasms
4
2019
2283
0.130
 Why?
Pregnancy Complications, Infectious
1
2002
397
0.130
 Why?
Leukocyte Common Antigens
1
2017
90
0.130
 Why?
Anion Transport Proteins
1
2017
8
0.130
 Why?
Survival Rate
5
2020
1934
0.130
 Why?
Salpingectomy
2
2015
15
0.130
 Why?
beta Catenin
1
2019
253
0.130
 Why?
Fatty Acids
1
2020
445
0.130
 Why?
Gestational Trophoblastic Disease
1
2016
6
0.130
 Why?
Curettage
1
2016
8
0.130
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.130
 Why?
Keratins
1
2017
171
0.130
 Why?
Mice
10
2024
17828
0.130
 Why?
Megestrol Acetate
1
2016
2
0.130
 Why?
Sexual Dysfunction, Physiological
1
2017
66
0.120
 Why?
Carcinoma, Neuroendocrine
1
2016
34
0.120
 Why?
Minority Groups
1
2018
275
0.120
 Why?
Neoplasms, Squamous Cell
1
1996
4
0.120
 Why?
Risk Factors
6
2016
10385
0.120
 Why?
Colony Count, Microbial
1
2016
122
0.120
 Why?
Standard of Care
1
2016
77
0.120
 Why?
Gynecology
1
2018
177
0.120
 Why?
Medroxyprogesterone Acetate
1
2015
36
0.120
 Why?
Adenoviridae
1
1996
200
0.120
 Why?
Venous Thromboembolism
1
2020
324
0.120
 Why?
Cell Survival
4
2025
1126
0.120
 Why?
Brachytherapy
1
2016
128
0.120
 Why?
Gene Expression Profiling
2
2019
1746
0.120
 Why?
Keratin-5
1
2015
49
0.120
 Why?
Molecular Targeted Therapy
1
2018
413
0.120
 Why?
Anticoagulants
1
2020
667
0.120
 Why?
Tretinoin
1
1996
123
0.120
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2017
984
0.120
 Why?
Tamoxifen
1
2016
202
0.110
 Why?
Chemoradiotherapy
1
2016
229
0.110
 Why?
Immunohistochemistry
3
2016
1730
0.110
 Why?
Combined Modality Therapy
4
2020
1235
0.110
 Why?
Cell Proliferation
5
2024
2480
0.110
 Why?
Antineoplastic Agents, Hormonal
1
2015
168
0.110
 Why?
CA-125 Antigen
2
2008
13
0.110
 Why?
Abdominal Abscess
1
2014
25
0.110
 Why?
Xenograft Model Antitumor Assays
3
2024
870
0.110
 Why?
Mice, SCID
2
2012
368
0.110
 Why?
Kaplan-Meier Estimate
4
2020
897
0.100
 Why?
Endometrium
1
2014
60
0.100
 Why?
Surgeons
1
2018
327
0.100
 Why?
Reoperation
1
2016
579
0.100
 Why?
Glycoproteins
1
2015
354
0.100
 Why?
Cytokines
1
2002
2083
0.100
 Why?
Lipid Metabolism
1
2017
523
0.100
 Why?
Immunotherapy
1
2018
633
0.100
 Why?
Cell Cycle
2
2025
593
0.100
 Why?
Double-Blind Method
4
2025
1949
0.100
 Why?
Case-Control Studies
5
2025
3574
0.100
 Why?
Interpersonal Relations
1
2017
413
0.100
 Why?
Quality of Health Care
1
2018
657
0.100
 Why?
Proto-Oncogene Proteins c-akt
2
2016
442
0.100
 Why?
Transforming Growth Factor beta
1
1996
488
0.100
 Why?
Pelvic Neoplasms
1
2013
25
0.100
 Why?
Models, Biological
3
2019
1810
0.100
 Why?
Genes, Tumor Suppressor
3
1998
81
0.100
 Why?
Plasmids
1
2014
359
0.100
 Why?
Young Adult
5
2020
13371
0.100
 Why?
Antigens, CD
1
2015
537
0.100
 Why?
Gardnerella vaginalis
2
2002
4
0.090
 Why?
RNA, Messenger
2
2012
2815
0.090
 Why?
Antibody Specificity
1
2012
187
0.090
 Why?
Escherichia coli
1
2016
827
0.090
 Why?
Cell Division
2
2008
794
0.090
 Why?
Endocrine Gland Neoplasms
1
2011
1
0.090
 Why?
Transplantation, Heterologous
1
2012
193
0.090
 Why?
Neoplastic Stem Cells
1
2015
397
0.090
 Why?
RNA, Small Interfering
3
2020
626
0.090
 Why?
Cyclin D1
1
2011
68
0.090
 Why?
Drug Synergism
2
2011
367
0.090
 Why?
Proteasome Inhibitors
1
2011
43
0.090
 Why?
MicroRNAs
1
2017
676
0.080
 Why?
DNA
1
2017
1441
0.080
 Why?
Adenocarcinoma, Mucinous
1
2011
74
0.080
 Why?
Transfection
2
2007
942
0.080
 Why?
Peptides
1
2015
980
0.080
 Why?
Cadherins
1
2011
203
0.080
 Why?
Neoplasm Invasiveness
3
2016
501
0.080
 Why?
Inflammation
1
2020
2853
0.080
 Why?
Age Factors
5
2016
3276
0.080
 Why?
Lymphoma
1
2011
229
0.080
 Why?
Skin Transplantation
1
2009
85
0.070
 Why?
Anastomosis, Surgical
1
2009
158
0.070
 Why?
Urokinase-Type Plasminogen Activator
1
2008
29
0.070
 Why?
Adaptor Proteins, Signal Transducing
1
2011
429
0.070
 Why?
G2 Phase
1
2008
39
0.070
 Why?
Adolescent
5
2020
21581
0.070
 Why?
Papillomaviridae
2
2002
132
0.070
 Why?
TOR Serine-Threonine Kinases
1
2011
416
0.070
 Why?
Radiation-Protective Agents
1
2008
26
0.070
 Why?
Rectum
1
2009
188
0.070
 Why?
Heterografts
2
2019
135
0.070
 Why?
Models, Statistical
1
2011
665
0.070
 Why?
Genes, BRCA1
2
1998
41
0.070
 Why?
Microsatellite Instability
2
2019
41
0.070
 Why?
Class I Phosphatidylinositol 3-Kinases
2
2019
97
0.070
 Why?
Urinary Bladder
1
2009
186
0.070
 Why?
Cell Culture Techniques
2
2020
365
0.060
 Why?
Cysteine
1
2008
204
0.060
 Why?
Tumor Suppressor Protein p53
3
2019
527
0.060
 Why?
PTEN Phosphohydrolase
2
2019
163
0.060
 Why?
Gynecologic Surgical Procedures
2
2020
67
0.060
 Why?
Adenosarcoma
2
2005
2
0.060
 Why?
Models, Animal
1
2008
396
0.060
 Why?
Proportional Hazards Models
3
2020
1281
0.060
 Why?
Follow-Up Studies
4
2020
5152
0.060
 Why?
Signal Transduction
4
2012
5092
0.060
 Why?
Indazoles
2
2019
67
0.060
 Why?
Retrospective Studies
6
2020
15901
0.060
 Why?
Polymerase Chain Reaction
4
2002
1047
0.060
 Why?
Maintenance Chemotherapy
1
2025
36
0.060
 Why?
Colposcopy
2
2003
21
0.060
 Why?
Length of Stay
3
2015
1237
0.060
 Why?
Intestinal Neoplasms
1
2005
31
0.060
 Why?
Cell Count
2
2015
325
0.060
 Why?
Ovary
1
2007
223
0.060
 Why?
Neoplasm Proteins
3
1998
433
0.060
 Why?
Sexual Behavior
1
2009
488
0.060
 Why?
Ultraviolet Rays
1
2008
399
0.060
 Why?
Germ-Line Mutation
2
1996
170
0.060
 Why?
Chicago
1
2004
63
0.060
 Why?
United States
5
2022
15074
0.060
 Why?
Disease Progression
3
2019
2752
0.050
 Why?
Peptide Fragments
1
2008
694
0.050
 Why?
Tumor Cells, Cultured
2
1996
956
0.050
 Why?
Antioxidants
1
2008
593
0.050
 Why?
Transcription Factors
4
2011
1701
0.050
 Why?
Blood Loss, Surgical
2
2015
107
0.050
 Why?
Survival Analysis
4
2020
1311
0.050
 Why?
Activating Transcription Factor 6
1
2023
20
0.050
 Why?
Receptors, Estrogen
2
2015
437
0.050
 Why?
Transcription Factor AP-1
1
2023
88
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
13
0.050
 Why?
Neoplasm Metastasis
2
2015
667
0.050
 Why?
Trichomonas vaginalis
1
2002
13
0.050
 Why?
Vaginal Neoplasms
1
2001
18
0.050
 Why?
Gene Expression
1
2007
1487
0.050
 Why?
Medical Oncology
1
2024
304
0.050
 Why?
Phosphatidylinositol 3-Kinases
2
2016
368
0.050
 Why?
Women's Health
1
2004
372
0.050
 Why?
Risk Assessment
3
2016
3466
0.050
 Why?
Yeasts
1
2002
53
0.050
 Why?
Vaginosis, Bacterial
1
2001
13
0.050
 Why?
Vaginal Diseases
1
2001
20
0.050
 Why?
Cell Nucleus
1
2025
608
0.040
 Why?
Endometriosis
1
2001
53
0.040
 Why?
DNA, Neoplasm
2
1998
158
0.040
 Why?
Quality of Life
2
2025
2962
0.040
 Why?
Pregnancy
3
2016
6870
0.040
 Why?
DNA Primers
1
2002
509
0.040
 Why?
Vulvectomy
1
2020
2
0.040
 Why?
Epithelial Cells
1
2007
1103
0.040
 Why?
Dermatofibrosarcoma
1
2020
7
0.040
 Why?
Histiocytoma, Malignant Fibrous
1
2020
5
0.040
 Why?
Hospitals, Urban
1
2001
138
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
51
0.040
 Why?
Disease Models, Animal
2
2024
4316
0.040
 Why?
Databases, Factual
2
2016
1409
0.040
 Why?
Medically Uninsured
1
2001
135
0.040
 Why?
Liposarcoma
1
2020
27
0.040
 Why?
DNA Repair
1
2022
229
0.040
 Why?
Alleles
3
2017
890
0.040
 Why?
Anoikis
1
2020
31
0.040
 Why?
Hemocyanins
1
2019
61
0.040
 Why?
Interleukin-10
1
2002
304
0.040
 Why?
Diagnosis, Differential
2
2019
1482
0.040
 Why?
Prospective Studies
4
2016
7661
0.040
 Why?
Chitinase-3-Like Protein 1
1
2019
19
0.040
 Why?
Enzyme-Linked Immunosorbent Assay
1
2002
850
0.040
 Why?
Rhabdomyosarcoma
1
2020
74
0.040
 Why?
Logistic Models
1
2004
2093
0.040
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2019
26
0.040
 Why?
SEER Program
1
2020
220
0.040
 Why?
Intramolecular Oxidoreductases
1
2019
68
0.040
 Why?
Radiotherapy
1
2020
207
0.040
 Why?
DNA Damage
1
2022
422
0.040
 Why?
DNA Polymerase II
1
2019
35
0.040
 Why?
Poly-ADP-Ribose Binding Proteins
1
2019
33
0.040
 Why?
Lymphatic Metastasis
1
2020
323
0.040
 Why?
Gene Knockdown Techniques
1
2020
329
0.040
 Why?
Chromosomes, Human, Pair 7
1
1998
18
0.040
 Why?
Cell Cycle Checkpoints
1
2019
97
0.040
 Why?
Cytoskeletal Proteins
1
2019
156
0.040
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2019
129
0.040
 Why?
Mitosis
1
2019
192
0.040
 Why?
Microtubule-Associated Proteins
1
2019
195
0.040
 Why?
Europe
1
2019
407
0.030
 Why?
Interleukin-1
1
2002
966
0.030
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
1998
35
0.030
 Why?
AMP-Activated Protein Kinases
1
2019
200
0.030
 Why?
Image Cytometry
1
2017
9
0.030
 Why?
Interleukin-6
1
2002
785
0.030
 Why?
Wnt Signaling Pathway
1
2019
197
0.030
 Why?
Chromosomes, Human, Pair 14
1
1997
20
0.030
 Why?
Ganciclovir
1
1996
53
0.030
 Why?
Chromosome Deletion
1
1997
114
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Socioeconomic Factors
1
2001
1312
0.030
 Why?
Chorionic Gonadotropin
1
2016
78
0.030
 Why?
Mass Spectrometry
1
2019
739
0.030
 Why?
Oxidation-Reduction
1
2020
1076
0.030
 Why?
Cell Separation
1
2017
317
0.030
 Why?
Ifosfamide
1
1996
38
0.030
 Why?
Time Factors
2
2019
6869
0.030
 Why?
AC133 Antigen
1
2015
20
0.030
 Why?
Cell Differentiation
2
2011
1994
0.030
 Why?
Cell Line, Transformed
1
1996
145
0.030
 Why?
Tissue Array Analysis
1
2015
51
0.030
 Why?
Hospital Charges
1
1996
44
0.030
 Why?
Hospitals, Teaching
1
2016
115
0.030
 Why?
Marriage
1
2017
122
0.030
 Why?
Caspase 3
1
2016
251
0.030
 Why?
Cystadenocarcinoma, Papillary
1
1995
4
0.030
 Why?
Carboplatin
1
1996
146
0.030
 Why?
RNA-Binding Proteins
1
2019
430
0.030
 Why?
Tumor Burden
1
2016
307
0.030
 Why?
Cell Cycle Proteins
1
2019
617
0.030
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2015
65
0.030
 Why?
DNA Mismatch Repair
1
2015
46
0.030
 Why?
Ileus
1
2015
13
0.030
 Why?
Genes, p53
1
1995
68
0.030
 Why?
Disease Management
1
2019
621
0.030
 Why?
Urinary Retention
1
2015
22
0.030
 Why?
Income
1
2016
207
0.030
 Why?
Female Urogenital Diseases
1
2014
6
0.030
 Why?
Taxoids
1
2015
101
0.030
 Why?
RNA Interference
1
2016
468
0.030
 Why?
Elective Surgical Procedures
1
2016
192
0.030
 Why?
Antigens, Neoplasm
1
2017
316
0.030
 Why?
Multivariate Analysis
2
1996
1497
0.030
 Why?
Receptors, Androgen
1
2015
150
0.030
 Why?
Morbidity
1
2015
321
0.030
 Why?
Drug Administration Schedule
1
2016
769
0.030
 Why?
Sensitivity and Specificity
1
2019
1939
0.030
 Why?
Reference Values
1
1996
801
0.030
 Why?
Blood Volume
1
2014
65
0.030
 Why?
Intraoperative Complications
1
2015
148
0.030
 Why?
Bleomycin
1
1996
247
0.030
 Why?
Bevacizumab
1
2015
139
0.030
 Why?
Histones
1
2019
632
0.030
 Why?
Infusions, Parenteral
1
2014
43
0.030
 Why?
Point Mutation
1
1995
238
0.030
 Why?
Polyethyleneimine
1
2014
17
0.030
 Why?
DNA, Viral
1
1996
365
0.030
 Why?
Pelvis
1
2015
113
0.030
 Why?
Hemostatics
1
2014
56
0.030
 Why?
Insurance, Health
1
2016
297
0.030
 Why?
Tumor Suppressor Proteins
1
2016
322
0.030
 Why?
Deoxycytidine
1
2015
192
0.030
 Why?
Receptors, Progesterone
1
2015
349
0.030
 Why?
Drainage
1
2014
172
0.030
 Why?
Anemia
1
2015
175
0.030
 Why?
Preoperative Care
1
2015
366
0.020
 Why?
Urban Population
1
2016
485
0.020
 Why?
Thrombocytopenia
1
2015
205
0.020
 Why?
Gene Transfer Techniques
1
2014
176
0.020
 Why?
Polymorphism, Single-Stranded Conformational
3
1998
25
0.020
 Why?
Patient Readmission
1
2018
703
0.020
 Why?
Referral and Consultation
1
2018
795
0.020
 Why?
Membrane Proteins
1
2019
1149
0.020
 Why?
Biomarkers
1
2024
4095
0.020
 Why?
Ultrasonography
1
2016
748
0.020
 Why?
Linear Models
1
1994
855
0.020
 Why?
Cholesterol
1
2014
403
0.020
 Why?
Zinc Finger E-box-Binding Homeobox 1
1
2011
23
0.020
 Why?
Analysis of Variance
1
1994
1317
0.020
 Why?
Perioperative Period
1
2011
64
0.020
 Why?
Rural Population
1
2016
582
0.020
 Why?
Protein Kinase Inhibitors
1
2017
907
0.020
 Why?
Mutant Proteins
1
2011
103
0.020
 Why?
DNA Fragmentation
1
2011
42
0.020
 Why?
Risk Reduction Behavior
1
2013
216
0.020
 Why?
Comorbidity
1
2016
1657
0.020
 Why?
Fas Ligand Protein
1
2011
60
0.020
 Why?
Hyperplasia
1
2011
176
0.020
 Why?
Neovascularization, Pathologic
1
2012
296
0.020
 Why?
Neoplasm Transplantation
1
2011
249
0.020
 Why?
Tomography, X-Ray Computed
2
2014
2697
0.020
 Why?
Administration, Oral
1
2012
787
0.020
 Why?
Polymorphism, Single Nucleotide
1
2017
2138
0.020
 Why?
Epithelial-Mesenchymal Transition
1
2011
210
0.020
 Why?
Antibodies, Monoclonal, Humanized
1
2015
814
0.020
 Why?
Pregnancy Complications
1
2014
538
0.020
 Why?
Anti-Bacterial Agents
2
2014
1811
0.020
 Why?
Regression Analysis
1
2011
1021
0.020
 Why?
Polyethylene Glycols
1
2014
631
0.020
 Why?
Receptors, Urokinase Plasminogen Activator
1
2008
15
0.020
 Why?
Patient Discharge
1
2015
915
0.020
 Why?
Blotting, Western
1
2011
1232
0.020
 Why?
Injections, Subcutaneous
1
2008
162
0.020
 Why?
Placebos
1
2008
197
0.020
 Why?
Mice, Hairless
1
2008
59
0.020
 Why?
Enzyme Inhibitors
1
2011
850
0.020
 Why?
Sulfonamides
1
2011
505
0.020
 Why?
Quality Improvement
1
2015
1215
0.020
 Why?
Molecular Sequence Data
3
1996
2925
0.020
 Why?
Chromosome Mapping
2
1998
505
0.020
 Why?
Genetic Markers
2
1998
344
0.020
 Why?
Receptors, Cell Surface
1
2008
394
0.020
 Why?
Frameshift Mutation
2
1996
32
0.020
 Why?
Cross-Sectional Studies
1
2017
5530
0.010
 Why?
Gene Deletion
2
1998
389
0.010
 Why?
Carcinosarcoma
1
2005
23
0.010
 Why?
DNA Mutational Analysis
2
1996
397
0.010
 Why?
Cohort Studies
1
2015
5744
0.010
 Why?
Colorado
1
2014
4543
0.010
 Why?
Severity of Illness Index
1
2011
2849
0.010
 Why?
Obesity
1
2016
2994
0.010
 Why?
Base Sequence
2
1996
2176
0.010
 Why?
Electrophoresis, Gel, Pulsed-Field
1
2001
24
0.010
 Why?
Metronidazole
1
2001
20
0.010
 Why?
Genes, rRNA
1
2001
42
0.010
 Why?
Microbial Sensitivity Tests
1
2001
348
0.010
 Why?
DNA, Bacterial
1
2001
336
0.010
 Why?
RNA, Ribosomal, 16S
1
2001
554
0.010
 Why?
Loss of Heterozygosity
1
1998
51
0.010
 Why?
Microsatellite Repeats
1
1998
160
0.010
 Why?
Actuarial Analysis
1
1996
22
0.010
 Why?
Ecosystem
1
2001
573
0.010
 Why?
Genes, Neoplasm
1
1995
22
0.010
 Why?
BRCA1 Protein
1
1995
77
0.010
 Why?
Age of Onset
1
1996
521
0.010
 Why?
Sequence Analysis, DNA
1
1998
824
0.010
 Why?
Introns
1
1995
254
0.010
 Why?
Exons
1
1995
352
0.010
 Why?
Amino Acid Sequence
1
1995
2159
0.010
 Why?
Male
1
2017
68250
0.010
 Why?
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (455) concept(s)
_
Co-Authors Expand Description
See all (54) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)